Tiziana Life Sciences Ltd Com Stock Price, News & Analysis

Tiziana Life Sciences (Nasdaq: TLSA) announced that Panetta Partners Limited acquired 20,000 common shares at $0.75 each, increasing Executive Chairman Gabriele Cerrone's ownership from 37.60% to 37.61%. Tiziana is focused on developing innovative immunotherapies through novel drug delivery methods, including intranasal and oral routes, which show potential for better efficacy and safety compared to traditional IV methods. Their lead candidates, intranasal foralumab and milciclib, have shown favorable safety profiles and clinical responses in studies.

Tiziana Life Sciences (Nasdaq: TLSA) announced a study showing improved cognitive function and restored microglia homeostasis in animal models of Alzheimer’s disease. The research focused on intranasal anti-CD3 monoclonal antibody and was presented at the AAIC on July 31, 2022. With promising results, the company is considering clinical trials of Foralumab in Alzheimer’s patients. Dr. Howard Weiner emphasized its potential to modulate microglial activity and reduce inflammation, making it a novel approach for treating progressive neurological disorders.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced the appointment of Matthew Davis, MD, RPh as the Chief Medical Officer and Acting Chief Scientific Officer, effective immediately. Dr. Davis, with 25 years of pharmaceutical experience and notable FDA approvals under his belt, is expected to drive Tiziana's shift towards proof-of-concept clinical trials. His leadership is aimed at enhancing the development of therapies for Secondary-Progressive Multiple Sclerosis, Crohn's Disease, and KRAS+ NSCLC.

Tiziana Life Sciences (NASDAQ: TLSA) announced the resignation of Dr. Kunwar Shailubhai as CEO, CSO, and Board director effective August 1, 2022, due to personal reasons. The resignation is not related to any operational disagreements. Gabriele Cerrone, Executive Chairman, will serve as interim CEO while the Board searches for a permanent replacement. The company continues to advance its foralumab clinical programs and will provide progress updates in due course.

Tiziana Life Sciences (TLSA) announced on June 14, 2022, that it received a notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price for continued listing on the Nasdaq Global Market. The Company has 180 days to regain compliance by maintaining the closing bid price at or above $1.00 for at least ten consecutive business days. The notice does not affect the current trading of its securities. Tiziana aims to resolve this deficiency and may consider options to meet the bid price requirement before the compliance deadline of December 12, 2022.

Tiziana Life Sciences (Nasdaq: TLSA) announced on June 10, 2022, that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, purchased 50,000 common shares at $0.88 each. This acquisition increased Cerrone's stake from 37.60% to 37.64%. Tiziana specializes in developing innovative immunotherapy delivery methods, focusing on alternative routes such as nasal, oral, and inhalation. Their leading candidates include intranasal foralumab and milciclib, both of which have shown favorable safety profiles in clinical studies.

Tiziana Life Sciences PLC (NASDAQ: TLSA) announced positive clinical results for its second patient in a secondary progressive multiple sclerosis (SPMS) trial. The patient showed improvements in PET analysis and neurologic exams after three months of treatment with intranasal foralumab. Following these findings, the FDA approved the enrollment of eight additional patients in the trial. Tiziana aims to escalate dosing to potentially enhance clinical benefits. The company anticipates enrolling the third patient by July 2022 and expects to release data on all ten patients in 2023.

Tiziana Life Sciences (TLSA) announced positive clinical outcomes from its ongoing study on Foralumab for patients with Secondary Progressive Multiple Sclerosis (SPMS) during a recent interview. Conducted at Brigham and Women’s Hospital, the trial highlights the potential of Foralumab, the only fully human anti-CD3 mAb, in managing autoimmune diseases. The treatment has shown favorable safety profiles and effective immune response modulation. Tiziana focuses on innovative drug delivery technologies, aiming to improve patient outcomes by offering alternative routes for immunotherapy.

Tiziana Life Sciences PLC (NASDAQ: TLSA) announced positive clinical results for its second patient with secondary progressive multiple sclerosis (SPMS) on June 8, 2022. The patient demonstrated significant clinical improvements, including a 10-30% reduction in microglial activation after three months of treatment with intranasal foralumab. Following the success of the first two patients, the FDA has approved the enrollment of eight more patients under the Expanded Access Program. The company aims to investigate higher dosing levels and expects to enroll a third patient in July 2022.